Skip to main content
Amoéba logo

Amoéba — Investor Relations & Filings

Ticker · ALMIB ISIN · FR0011051598 LEI · 9695005QNE7C8Z0LXU64 PA Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country FR France
Listing PA ALMIB

About Amoéba

https://amoeba-nature.com/en/

Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.

Recent filings

Filing Released Lang Actions
Amoéba has obtained a new emergency authorization for the use of the AXPERA biocontrol solution to protect French vineyards
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an emergency marketing authorization from a French regulatory authority for the company’s biocontrol product. It is not a financial report (10-K, IR, ER), governance document (AGM, PSI, CGR), share transaction, dividend, or capital raising notice. It does not present financial results or detailed ESG data, nor is it announcing the publication of another report. This is a general regulatory announcement that does not fit any other specific category, making Regulatory Filings (RNS) the appropriate classification.
2026-04-28 English
Amoéba obtient une nouvelle autorisation d'urgence pour l'utilisation de la solution de biocontrôle AXPERA afin de protéger les vignobles français
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing that Amoeba obtained a new emergency phytosanitary marketing authorization for its biocontrol product AXPERA. It does not present financial results, management changes, share transactions, or dividend information. It is a regulatory announcement regarding product approval and thus falls under the fallback category for miscellaneous regulatory filings. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-04-28 French
Amoéba and Koppert highlight the potential of AXPERA technology in Brazil for strategic crops
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing field trial results and strategic commercial plans for the AXPERA technology in Brazil. It contains no financial results (so it’s not an Earnings Release), no regulatory report attachment (so it’s not RPA), no management changes, no share transactions, no dividend or capital change, no M&A, no legal proceedings, and no in‐depth ESG metrics. It is a general business announcement by a listed company, fitting the fallback category for miscellaneous regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2026-04-13 English
Amoéba et Koppert mettent en évidence le potentiel de la technologie AXPERA au Brésil sur des cultures stratégiques
Regulatory Filings Classification · 1% confidence The document is a corporate press release by Amoeba announcing field trial results and market potential for its AXPERA biofungicide in Brazil. It does not present financial results (not an earnings release or interim/annual report), nor does it relate to management changes, M&A, share transactions, dividends, regulatory or legal notices, or AGM materials. It is a general corporate announcement with no specific category match, so under the taxonomy it falls into the catch‐all “Regulatory Filings” category (RNS).
2026-04-13 French
Amoéba annonce le succès de son augmentation de capital et lève 6,67 M EUR
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the success of a private placement and the issuance of new shares, detailing the number of new shares, pricing, capital structure before and after, and funding use. This is an announcement of a share issue/capital change (new share issuance). Therefore, it falls under ‘Share Issue/Capital Change’ (SHA).
2026-03-26 French
Amoéba announces the success of its capital increase and raises EUR 6.67 million
Share Issue/Capital Change Classification · 1% confidence The document is a press release announcing the successful completion of a capital increase via a private placement and detailing the issuance of new shares, pricing, share count, and post-transaction shareholding structure. This is a direct announcement of a new share issue and capital structure change, matching the “Share Issue/Capital Change” category (Code: SHA).
2026-03-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.